Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and pharmacokinetics of ERX-963 in adults with myotonic dystrophy type 1 has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy
• Myotonic Dystrophy Type

Drugs mentioned

• ERX-963

Snippet

Sponsor: Expansion Therapeutics, Inc. | Conditions: Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy | Phase 1 | Status: COMPLETED | Results posted: 2021-06-23